PGEN vs. CLLS, LUNA, BASI, SYRE, AKRO, MNKD, DAWN, ABCL, MIRM, and CALT
Should you be buying Precigen stock or one of its competitors? The main competitors of Precigen include Cellectis (CLLS), Luna Innovations (LUNA), Bioanalytical Systems (BASI), Spyre Therapeutics (SYRE), Akero Therapeutics (AKRO), MannKind (MNKD), Day One Biopharmaceuticals (DAWN), AbCellera Biologics (ABCL), Mirum Pharmaceuticals (MIRM), and Calliditas Therapeutics AB (publ) (CALT).
Precigen (NASDAQ:PGEN) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.
33.5% of Precigen shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 41.7% of Precigen shares are owned by company insiders. Comparatively, 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Precigen presently has a consensus price target of $9.00, suggesting a potential upside of 542.86%. Cellectis has a consensus price target of $8.50, suggesting a potential upside of 213.65%. Given Precigen's higher probable upside, analysts clearly believe Precigen is more favorable than Cellectis.
In the previous week, Cellectis had 11 more articles in the media than Precigen. MarketBeat recorded 12 mentions for Cellectis and 1 mentions for Precigen. Precigen's average media sentiment score of 1.87 beat Cellectis' score of 0.53 indicating that Precigen is being referred to more favorably in the media.
Precigen received 23 more outperform votes than Cellectis when rated by MarketBeat users. However, 67.95% of users gave Cellectis an outperform vote while only 67.08% of users gave Precigen an outperform vote.
Precigen has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.08, suggesting that its stock price is 208% more volatile than the S&P 500.
Precigen has higher revenue and earnings than Cellectis. Precigen is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.
Cellectis has a net margin of -529.81% compared to Precigen's net margin of -1,781.72%. Precigen's return on equity of -65.36% beat Cellectis' return on equity.
Summary
Precigen beats Cellectis on 10 of the 18 factors compared between the two stocks.
Get Precigen News Delivered to You Automatically
Sign up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Precigen Competitors List
Related Companies and Tools
